{
  "DOI": "10.1038/s41437-022-00533-1",
  "ISSN": [
    "0018-067X",
    "1365-2540"
  ],
  "URL": "http://dx.doi.org/10.1038/s41437-022-00533-1",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eCancer is a disease of the genome, therefore, its development has a clear Mendelian component, demonstrated by well-studied genes such as \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e and \u003cjats:italic\u003eBRCA2\u003c/jats:italic\u003e in breast cancer risk. However, it is known that a single genetic variant is not enough for cancer to develop leading to the theory of multistage carcinogenesis. In many cases, it is a sequence of events, acquired somatic mutations, or simply polygenic components with strong epigenetic effects, such as in the case of brain tumours. The expression of many genes is the product of the complex interplay between several factors, including the organism’s genotype (in most cases Mendelian-inherited), genetic instability, epigenetic factors (non-Mendelian-inherited) as well as the immune response of the host, to name just a few. In recent years the importance of the immune system has been elevated, especially in the light of the immune checkpoint genes discovery and the subsequent development of their inhibitors. As the expression of these genes normally suppresses self-immunoreactivity, their expression by tumour cells prevents the elimination of the tumour by the immune system. These discoveries led to the rapid growth of the field of immuno-oncology that offers new possibilities of long-lasting and effective treatment options. Here we discuss the recent advances in the understanding of the key mechanisms controlling the expression of immune checkpoint genes in tumour cells.\u003c/jats:p\u003e",
  "alternative-id": [
    "533"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "20 December 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "29 March 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "30 March 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "22 April 2022"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "PAS was a shareholder and the managing director of the company SmartImmune Ltd. The remaining authors declare the absence of any commercial or financial relationships that could be construed as a potential competing interests."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-5134-0975",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Dobosz",
      "given": "Paula",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-9464-7475",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Stempor",
      "given": "Przemysław A.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-1559-8976",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ramírez Moreno",
      "given": "Miguel",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-3780-8164",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Bulgakova",
      "given": "Natalia A.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Heredity"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        4,
        22
      ]
    ],
    "date-time": "2022-04-22T13:07:19Z",
    "timestamp": 1650632839000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        10,
        22
      ]
    ],
    "date-time": "2022-10-22T02:04:18Z",
    "timestamp": 1666404258000
  },
  "indexed": {
    "date-parts": [
      [
        2023,
        12,
        13
      ]
    ],
    "date-time": "2023-12-13T11:18:08Z",
    "timestamp": 1702466288066
  },
  "is-referenced-by-count": 4,
  "issn-type": [
    {
      "type": "print",
      "value": "0018-067X"
    },
    {
      "type": "electronic",
      "value": "1365-2540"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2022,
        4,
        22
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2022,
          7
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            4,
            22
          ]
        ],
        "date-time": "2022-04-22T00:00:00Z",
        "timestamp": 1650585600000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            4,
            22
          ]
        ],
        "date-time": "2022-04-22T00:00:00Z",
        "timestamp": 1650585600000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41437-022-00533-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41437-022-00533-1",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41437-022-00533-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "64-74",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2022,
        4,
        22
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        4,
        22
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2022,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/ni.3753",
      "author": "B Afzali",
      "doi-asserted-by": "publisher",
      "first-page": "813",
      "journal-title": "Nat Immunol",
      "key": "533_CR1",
      "unstructured": "Afzali B, Grönholm J, Vandrovcova J, O’Brien C, Sun H-W, Vanderleyden I et al. (2017) BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat Immunol 18:813–823",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1158/2159-8290.CD-13-0310",
      "author": "EA Akbay",
      "doi-asserted-by": "publisher",
      "first-page": "1355",
      "journal-title": "Cancer Discov",
      "key": "533_CR2",
      "unstructured": "Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL et al. (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3:1355–1363",
      "volume": "3",
      "year": "2013"
    },
    {
      "DOI": "10.3390/jpm5020213",
      "author": "I Akhmetov",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "journal-title": "JPM",
      "key": "533_CR3",
      "unstructured": "Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju P (2015) Market access advancements and challenges in “Drug-Companion Diagnostic Test” co-development in Europe. JPM 5:213–228",
      "volume": "5",
      "year": "2015"
    },
    {
      "DOI": "10.1186/s13000-021-01151-x",
      "author": "M Akhtar",
      "doi-asserted-by": "publisher",
      "first-page": "94",
      "journal-title": "Diagn Pathol",
      "key": "533_CR4",
      "unstructured": "Akhtar M, Rashid S, Al-Bozom IA (2021) PD−L1 immunostaining: what pathologists need to know. Diagn Pathol 16:94",
      "volume": "16",
      "year": "2021"
    },
    {
      "DOI": "10.1182/blood-2011-01-325266",
      "author": "SM Amos",
      "doi-asserted-by": "publisher",
      "first-page": "499",
      "journal-title": "Blood",
      "key": "533_CR5",
      "unstructured": "Amos SM, Duong CPM, Westwood JA, Ritchie DS, Junghans RP, Darcy PK et al. (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118:499–509",
      "volume": "118",
      "year": "2011"
    },
    {
      "DOI": "10.1038/cdd.2009.69",
      "author": "RI Aqeilan",
      "doi-asserted-by": "publisher",
      "first-page": "215",
      "journal-title": "Cell Death Differ",
      "key": "533_CR6",
      "unstructured": "Aqeilan RI, Calin GA, Croce CM (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17:215–220",
      "volume": "17",
      "year": "2010"
    },
    {
      "DOI": "10.1038/bjc.1954.1",
      "author": "P Armitage",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Br J Cancer",
      "key": "533_CR7",
      "unstructured": "Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8:1–12",
      "volume": "8",
      "year": "1954"
    },
    {
      "author": "L Armstrong",
      "key": "533_CR8",
      "unstructured": "Armstrong L (2014) Epigenetics. Garland Science, New York, NY",
      "volume-title": "Epigenetics.",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s12325-019-01051-z",
      "author": "S Arora",
      "doi-asserted-by": "publisher",
      "first-page": "2638",
      "journal-title": "Adv Ther",
      "key": "533_CR9",
      "unstructured": "Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P et al. (2019) Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther 36:2638–2678",
      "volume": "36",
      "year": "2019"
    },
    {
      "DOI": "10.1155/2013/148014",
      "author": "A Assawamakin",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "BioMed Res Int",
      "key": "533_CR10",
      "unstructured": "Assawamakin A, Prueksaaroon S, Kulawonganunchai S, Shaw PJ, Varavithya V, Ruangrajitpakorn T et al. (2013) Biomarker selection and classification of “Omics” data using a two-step Bayes classification framework. BioMed Res Int 2013:1–9",
      "volume": "2013",
      "year": "2013"
    },
    {
      "DOI": "10.1172/JCI91190",
      "author": "M Ayers",
      "doi-asserted-by": "publisher",
      "first-page": "2930",
      "journal-title": "J Clin Investig",
      "key": "533_CR11",
      "unstructured": "Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al. (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127:2930–2940",
      "volume": "127",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s40364-020-00209-0",
      "author": "R Bai",
      "doi-asserted-by": "publisher",
      "journal-title": "Biomark Res",
      "key": "533_CR12",
      "unstructured": "Bai R, Lv Z, Xu D, Cui J (2020) Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 8:34",
      "volume": "8",
      "year": "2020"
    },
    {
      "DOI": "10.3390/ijms20092241",
      "author": "D Banik",
      "doi-asserted-by": "publisher",
      "first-page": "2241",
      "journal-title": "IJMS",
      "key": "533_CR13",
      "unstructured": "Banik D, Moufarrij S, Villagra A (2019) Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy. IJMS 20:2241",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1038/cr.2011.22",
      "author": "AJ Bannister",
      "doi-asserted-by": "publisher",
      "first-page": "381",
      "journal-title": "Cell Res",
      "key": "533_CR14",
      "unstructured": "Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21:381–395",
      "volume": "21",
      "year": "2011"
    },
    {
      "DOI": "10.1084/jem.2046fta",
      "author": "H Bashyam",
      "doi-asserted-by": "publisher",
      "first-page": "1243",
      "journal-title": "J Exp Med",
      "key": "533_CR15",
      "unstructured": "Bashyam H (2007) CTLA-4: from conflict to clinic. J Exp Med 204:1243–1243",
      "volume": "204",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.ccr.2013.04.011",
      "author": "W Béguelin",
      "doi-asserted-by": "publisher",
      "first-page": "677",
      "journal-title": "Cancer Cell",
      "key": "533_CR16",
      "unstructured": "Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677–692",
      "volume": "23",
      "year": "2013"
    },
    {
      "DOI": "10.1172/JCI131234",
      "author": "A Berglund",
      "doi-asserted-by": "publisher",
      "first-page": "974",
      "journal-title": "J Clin Investig",
      "key": "533_CR17",
      "unstructured": "Berglund A, Mills M, Putney RM, Hamaidi I, Mulé J, Kim S (2020) Methylation of immune synapse genes modulates tumor immunogenicity. J Clin Investig 130:974–980",
      "volume": "130",
      "year": "2020"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-12-4300",
      "author": "WL Berry",
      "doi-asserted-by": "publisher",
      "first-page": "2936",
      "journal-title": "Cancer Res",
      "key": "533_CR18",
      "unstructured": "Berry WL, Janknecht R (2013) KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73:2936–2942",
      "volume": "73",
      "year": "2013"
    },
    {
      "DOI": "10.18632/oncotarget.17950",
      "author": "L Booth",
      "doi-asserted-by": "publisher",
      "first-page": "83155",
      "journal-title": "Oncotarget",
      "key": "533_CR19",
      "unstructured": "Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P (2017) HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget 8:83155–83170",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s42003-022-03098-1",
      "author": "JR Bradley",
      "doi-asserted-by": "publisher",
      "first-page": "156",
      "journal-title": "Commun Biol",
      "key": "533_CR20",
      "unstructured": "Bradley JR, Cannings TI (2022) Data-driven design of targeted gene panels for estimating immunotherapy biomarkers. Commun Biol 5:156",
      "volume": "5",
      "year": "2022"
    },
    {
      "DOI": "10.1200/JCO.2017.77.6385",
      "author": "JR Brahmer",
      "doi-asserted-by": "publisher",
      "first-page": "1714",
      "journal-title": "JCO",
      "key": "533_CR21",
      "unstructured": "Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO 36:1714–1768",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1056/NEJMoa1200694",
      "author": "JR Brahmer",
      "doi-asserted-by": "publisher",
      "first-page": "2455",
      "journal-title": "N Engl J Med",
      "key": "533_CR22",
      "unstructured": "Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P et al. (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465",
      "volume": "366",
      "year": "2012"
    },
    {
      "DOI": "10.1002/eji.200425857",
      "author": "C Brossard",
      "doi-asserted-by": "publisher",
      "first-page": "1741",
      "journal-title": "Eur J Immunol",
      "key": "533_CR23",
      "unstructured": "Brossard C, Feuillet V, Schmitt A, Randriamampita C, Romao M, Raposo G et al. (2005) Multifocal structure of the T cell - dendritic cell synapse. Eur J Immunol 35:1741–1753",
      "volume": "35",
      "year": "2005"
    },
    {
      "DOI": "10.1084/jem.20192179",
      "author": "KP Burke",
      "doi-asserted-by": "publisher",
      "first-page": "e20192179",
      "journal-title": "J Exp Med",
      "key": "533_CR24",
      "unstructured": "Burke KP, Grebinoski S, Sharpe AH, Vignali DAA (2021) Understanding adverse events of immunotherapy: a mechanistic perspective. J Exp Med 218:e20192179",
      "volume": "218",
      "year": "2021"
    },
    {
      "DOI": "10.1073/pnas.0307323101",
      "author": "GA Calin",
      "doi-asserted-by": "publisher",
      "first-page": "2999",
      "journal-title": "Proc Natl Acad Sci",
      "key": "533_CR25",
      "unstructured": "Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci 101:2999–3004",
      "volume": "101",
      "year": "2004"
    },
    {
      "DOI": "10.1056/NEJMoa1613493",
      "author": "DP Carbone",
      "doi-asserted-by": "publisher",
      "first-page": "2415",
      "journal-title": "N Engl J Med",
      "key": "533_CR26",
      "unstructured": "Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al. (2017) First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med 376:2415–2426",
      "volume": "376",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.semcancer.2012.06.008",
      "author": "DM Carone",
      "doi-asserted-by": "publisher",
      "first-page": "99",
      "journal-title": "Semin Cancer Biol",
      "key": "533_CR27",
      "unstructured": "Carone DM, Lawrence JB (2013) Heterochromatin Instability in cancer: from the Barr body to satellites and the nuclear periphery. Semin Cancer Biol 23:99–108",
      "volume": "23",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nri3405",
      "author": "L Chen",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "journal-title": "Nat Rev Immunol",
      "key": "533_CR28",
      "unstructured": "Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227–242",
      "volume": "13",
      "year": "2013"
    },
    {
      "DOI": "10.1038/ncomms6241",
      "author": "L Chen",
      "doi-asserted-by": "publisher",
      "journal-title": "Nat Commun",
      "key": "533_CR29",
      "unstructured": "Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA et al. (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1056/NEJMra0707704",
      "author": "F Ciardiello",
      "doi-asserted-by": "publisher",
      "first-page": "1160",
      "journal-title": "N. Engl J Med",
      "key": "533_CR30",
      "unstructured": "Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N. Engl J Med 358:1160–1174",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.1586/erm.09.62",
      "author": "DP Clark",
      "doi-asserted-by": "publisher",
      "first-page": "787",
      "journal-title": "Expert Rev Mol Diagnostics",
      "key": "533_CR31",
      "unstructured": "Clark DP (2009) Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Rev Mol Diagnostics 9:787–794",
      "volume": "9",
      "year": "2009"
    },
    {
      "DOI": "10.1016/j.jaut.2014.05.002",
      "author": "IR Cohen",
      "doi-asserted-by": "publisher",
      "first-page": "112",
      "journal-title": "J Autoimmun",
      "key": "533_CR32",
      "unstructured": "Cohen IR (2014) Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: a comprehensive review. J Autoimmun 54:112–117",
      "volume": "54",
      "year": "2014"
    },
    {
      "DOI": "10.1016/S1074-7613(02)00362-X",
      "author": "AV Collins",
      "doi-asserted-by": "publisher",
      "first-page": "201",
      "journal-title": "Immunity",
      "key": "533_CR33",
      "unstructured": "Collins AV, Brodie DW, Gilbert RJC, Iaboni A, Manso-Sancho R, Walse B et al. (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201–210",
      "volume": "17",
      "year": "2002"
    },
    {
      "DOI": "10.1186/s40425-018-0489-5",
      "author": "JM Conroy",
      "doi-asserted-by": "publisher",
      "journal-title": "j Immunother cancer",
      "key": "533_CR34",
      "unstructured": "Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B et al. (2019) Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. j Immunother cancer 7:18",
      "volume": "7",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.intimp.2020.106594",
      "author": "GR Danbaran",
      "doi-asserted-by": "publisher",
      "first-page": "106594",
      "journal-title": "Int Immunopharmacol",
      "key": "533_CR35",
      "unstructured": "Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G et al. (2020) How microRNAs affect the PD-L1 and its synthetic pathway in cancer. Int Immunopharmacol 84:106594",
      "volume": "84",
      "year": "2020"
    },
    {
      "DOI": "10.1634/theoncologist.2012-0465",
      "author": "EJB Derissen",
      "doi-asserted-by": "publisher",
      "first-page": "619",
      "journal-title": "Oncologist",
      "key": "533_CR37",
      "unstructured": "Derissen EJB, Beijnen JH, Schellens JHM (2013) Concise drug review: azacitidine and decitabine. Oncologist 18:619–624",
      "volume": "18",
      "year": "2013"
    },
    {
      "DOI": "10.1080/15592294.2020.1754675",
      "doi-asserted-by": "crossref",
      "key": "533_CR178",
      "unstructured": "de Vos L, Grünwald I, Bawden EG, Dietrich J, Scheckenbach K, Wiek C et al. (2020) The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics 15:1195–1212"
    },
    {
      "DOI": "10.1200/JCO.2009.27.2146",
      "author": "ML Disis",
      "doi-asserted-by": "publisher",
      "first-page": "4531",
      "journal-title": "JCO",
      "key": "533_CR38",
      "unstructured": "Disis ML (2010) Immune regulation of cancer. JCO 28:4531–4538",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.tranon.2019.10.018",
      "author": "P Dobosz",
      "doi-asserted-by": "publisher",
      "first-page": "193",
      "journal-title": "Transl Oncol",
      "key": "533_CR39",
      "unstructured": "Dobosz P, Stempor PA, Roszik J, Herman A, Layani A, Berger R et al. (2020) Checkpoint genes at the cancer side of the immunological synapse in bladder cancer. Transl Oncol 13:193–200",
      "volume": "13",
      "year": "2020"
    },
    {
      "DOI": "10.1093/gigascience/giab055",
      "author": "J Dockès",
      "doi-asserted-by": "publisher",
      "journal-title": "GigaScience",
      "key": "533_CR40",
      "unstructured": "Dockès J, Varoquaux G, Poline J-B (2021) Preventing dataset shift from breaking machine-learning biomarkers. GigaScience 10:giab055",
      "volume": "10",
      "year": "2021"
    },
    {
      "DOI": "10.18632/oncotarget.13895",
      "author": "Y Dong",
      "doi-asserted-by": "publisher",
      "first-page": "2171",
      "journal-title": "Oncotarget",
      "key": "533_CR41",
      "unstructured": "Dong Y, Sun Q, Zhang X (2017) PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 8:2171–2186",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41388-018-0347-4",
      "author": "P Dong",
      "doi-asserted-by": "publisher",
      "first-page": "5257",
      "journal-title": "Oncogene",
      "key": "533_CR42",
      "unstructured": "Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S et al. (2018) Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer. Oncogene 37:5257–5268",
      "volume": "37",
      "year": "2018"
    },
    {
      "DOI": "10.1158/2326-6066.CIR-14-0161",
      "author": "ML Dustin",
      "doi-asserted-by": "publisher",
      "first-page": "1023",
      "journal-title": "Cancer Immunol Res",
      "key": "533_CR43",
      "unstructured": "Dustin ML (2014) The immunological synapse. Cancer Immunol Res 2:1023–1033",
      "volume": "2",
      "year": "2014"
    },
    {
      "DOI": "10.1126/science.1076386",
      "author": "ML Dustin",
      "doi-asserted-by": "publisher",
      "first-page": "785",
      "journal-title": "Science",
      "key": "533_CR44",
      "unstructured": "Dustin ML, Colman DR (2002) Neural and immunological synaptic relations. Science 298:785–789",
      "volume": "298",
      "year": "2002"
    },
    {
      "DOI": "10.1073/pnas.88.8.3470",
      "author": "WS el-Deiry",
      "doi-asserted-by": "publisher",
      "first-page": "3470",
      "journal-title": "Proc Natl Acad Sci",
      "key": "533_CR36",
      "unstructured": "el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR et al. (1991) High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci 88:3470–3474",
      "volume": "88",
      "year": "1991"
    },
    {
      "DOI": "10.1038/nrc1840",
      "author": "A Esquela-Kerscher",
      "doi-asserted-by": "publisher",
      "first-page": "259",
      "journal-title": "Nat Rev Cancer",
      "key": "533_CR46",
      "unstructured": "Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269",
      "volume": "6",
      "year": "2006"
    },
    {
      "author": "M Esteller",
      "first-page": "3225",
      "journal-title": "Cancer Res",
      "key": "533_CR47",
      "unstructured": "Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229",
      "volume": "61",
      "year": "2001"
    },
    {
      "DOI": "10.1111/j.1600-065X.2008.00662.x",
      "author": "BT Fife",
      "doi-asserted-by": "publisher",
      "first-page": "166",
      "journal-title": "Immunological Rev",
      "key": "533_CR48",
      "unstructured": "Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunological Rev 224:166–182",
      "volume": "224",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nrg2290",
      "author": "W Filipowicz",
      "doi-asserted-by": "publisher",
      "first-page": "102",
      "journal-title": "Nat Rev Genet",
      "key": "533_CR49",
      "unstructured": "Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102–114",
      "volume": "9",
      "year": "2008"
    },
    {
      "DOI": "10.1126/science.1123940",
      "author": "SJ Fleire",
      "doi-asserted-by": "publisher",
      "first-page": "738",
      "journal-title": "Science",
      "key": "533_CR50",
      "unstructured": "Fleire SJ, Goldman JP, Carrasco YR, Weber M, Bray D, Batista FD (2006) B cell ligand discrimination through a spreading and contraction response. Science 312:738–741",
      "volume": "312",
      "year": "2006"
    },
    {
      "DOI": "10.1186/s40364-018-0122-2",
      "author": "L Gan",
      "doi-asserted-by": "publisher",
      "journal-title": "Biomark Res",
      "key": "533_CR51",
      "unstructured": "Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W (2018) Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res 6:10",
      "volume": "6",
      "year": "2018"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-16-1069",
      "author": "J George",
      "doi-asserted-by": "publisher",
      "first-page": "1220",
      "journal-title": "Clin Cancer Res",
      "key": "533_CR52",
      "unstructured": "George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH et al. (2017) Genomic amplification of CD274 (PD-L1) in small-cell lung cancer. Clin Cancer Res 23:1220–1226",
      "volume": "23",
      "year": "2017"
    },
    {
      "author": "I Girault",
      "first-page": "4415",
      "journal-title": "Clin Cancer Res",
      "key": "533_CR53",
      "unstructured": "Girault I, Tozlu S, Lidereau R, Bièche I (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9:4415–4422",
      "volume": "9",
      "year": "2003"
    },
    {
      "DOI": "10.1126/science.aan4236",
      "author": "V Gopalakrishnan",
      "doi-asserted-by": "publisher",
      "first-page": "97",
      "journal-title": "Science",
      "key": "533_CR54",
      "unstructured": "Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al. (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103",
      "volume": "359",
      "year": "2018"
    },
    {
      "DOI": "10.1126/science.285.5425.221",
      "author": "A Grakoui",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "journal-title": "Science",
      "key": "533_CR55",
      "unstructured": "Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM et al. (1999) The immunological synapse: a molecular machine controlling T cell activation. Science 285:221–227",
      "volume": "285",
      "year": "1999"
    },
    {
      "DOI": "10.1038/s41375-020-1003-x",
      "author": "X Gu",
      "doi-asserted-by": "publisher",
      "first-page": "1023",
      "journal-title": "Leukemia",
      "key": "533_CR56",
      "unstructured": "Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L et al. (2021) Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia 35:1023–1036",
      "volume": "35",
      "year": "2021"
    },
    {
      "DOI": "10.7150/jca.19477",
      "author": "C Gurrion",
      "doi-asserted-by": "publisher",
      "first-page": "2866",
      "journal-title": "J Cancer",
      "key": "533_CR57",
      "unstructured": "Gurrion C, Uriostegui M, Zurita M (2017) Heterochromatin reduction correlates with the increase of the KDM4B and KDM6A demethylases and the expression of pericentromeric DNA during the acquisition of a transformed phenotype. J Cancer 8:2866–2875",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2019.2535",
      "author": "A Haslam",
      "doi-asserted-by": "publisher",
      "first-page": "e192535",
      "journal-title": "JAMA Netw Open",
      "key": "533_CR58",
      "unstructured": "Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535",
      "volume": "2",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41568-019-0116-x",
      "author": "JJ Havel",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "journal-title": "Nat Rev Cancer",
      "key": "533_CR59",
      "unstructured": "Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150",
      "volume": "19",
      "year": "2019"
    },
    {
      "DOI": "10.1038/srep13110",
      "author": "J He",
      "doi-asserted-by": "publisher",
      "journal-title": "Sci Rep",
      "key": "533_CR60",
      "unstructured": "He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13110",
      "volume": "5",
      "year": "2015"
    },
    {
      "DOI": "10.1159/000494544",
      "author": "F He",
      "doi-asserted-by": "publisher",
      "first-page": "1178",
      "journal-title": "Cell Physiol Biochem",
      "key": "533_CR61",
      "unstructured": "He F, Zhou Y, Wang X, Li L, Geng Y, Wang Z et al. (2018) Functional polymorphisms of CTLA4 associated with aggressive periodontitis in the Chinese Han population. Cell Physiol Biochem 50:1178–1185",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s12253-020-00834-y",
      "author": "L Hegedűs",
      "doi-asserted-by": "publisher",
      "first-page": "2523",
      "journal-title": "Pathol Oncol Res",
      "key": "533_CR62",
      "unstructured": "Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B et al. (2020) HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res 26:2523–2535",
      "volume": "26",
      "year": "2020"
    },
    {
      "DOI": "10.1056/NEJMoa1003466",
      "author": "FS Hodi",
      "doi-asserted-by": "publisher",
      "first-page": "711",
      "journal-title": "N. Engl J Med",
      "key": "533_CR63",
      "unstructured": "Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl J Med 363:711–723",
      "volume": "363",
      "year": "2010"
    },
    {
      "DOI": "10.1038/ng1803",
      "author": "E Hornstein",
      "doi-asserted-by": "publisher",
      "first-page": "S20",
      "journal-title": "Nat Genet",
      "key": "533_CR64",
      "unstructured": "Hornstein E, Shomron N (2006) Canalization of development by microRNAs. Nat Genet 38:S20–S24",
      "volume": "38",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.archoralbio.2012.03.002",
      "author": "B Houshmand",
      "doi-asserted-by": "publisher",
      "first-page": "1218",
      "journal-title": "Arch Oral Biol",
      "key": "533_CR65",
      "unstructured": "Houshmand B, Rafiei A, Hajilooi M (2012) Influence of cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms in periodontitis. Arch Oral Biol 57:1218–1224",
      "volume": "57",
      "year": "2012"
    },
    {
      "DOI": "10.1002/bies.201600095",
      "author": "FS Howe",
      "doi-asserted-by": "publisher",
      "first-page": "e201600095",
      "journal-title": "BioEssays",
      "key": "533_CR66",
      "unstructured": "Howe FS, Fischl H, Murray SC, Mellor J (2017) Is H3K4me3 instructive for transcription activation? BioEssays 39:e201600095",
      "volume": "39",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s13148-021-01154-x",
      "author": "C Hu",
      "doi-asserted-by": "publisher",
      "first-page": "166",
      "journal-title": "Clin Epigenet",
      "key": "533_CR67",
      "unstructured": "Hu C, Liu X, Zeng Y, Liu J, Wu F (2021) DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenet 13:166",
      "volume": "13",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.jtho.2015.09.010",
      "doi-asserted-by": "crossref",
      "key": "533_CR68",
      "unstructured": "Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y et al. (2016) PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non–small cell lung cancer. J Thorac Oncol 11:62–71"
    },
    {
      "DOI": "10.21037/tlcr.2017.10.13",
      "author": "M Ilie",
      "doi-asserted-by": "publisher",
      "first-page": "S51",
      "journal-title": "Transl Lung Cancer Res",
      "key": "533_CR70",
      "unstructured": "Ilie M, Hofman P (2017) Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them. Transl Lung Cancer Res 6:S51–S54",
      "volume": "6",
      "year": "2017"
    },
    {
      "DOI": "10.3390/cells9061376",
      "author": "Y Ishida",
      "doi-asserted-by": "publisher",
      "first-page": "1376",
      "journal-title": "Cells",
      "key": "533_CR71",
      "unstructured": "Ishida Y (2020) PD-1: its discovery, involvement in cancer immunotherapy, and beyond. Cells 9:1376",
      "volume": "9",
      "year": "2020"
    },
    {
      "DOI": "10.1186/s12967-014-0218-x",
      "author": "F Jebbawi",
      "doi-asserted-by": "publisher",
      "journal-title": "J Transl Med",
      "key": "533_CR72",
      "unstructured": "Jebbawi F, Fayyad-Kazan H, Merimi M, Lewalle P, Verougstraete J-C, Leo O et al. (2014) A microRNA profile of human CD8+ regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. J Transl Med 12:218",
      "volume": "12",
      "year": "2014"
    },
    {
      "DOI": "10.2217/fon-2020-0119",
      "doi-asserted-by": "publisher",
      "key": "533_CR73",
      "unstructured": "John A, Qin B, Kalari KR, Wang L, Yu J (2020). Patient-specific multi-omics models and the application in personalized combination therapy. Fut Oncol https://doi.org/10.2217/fon-2020-0119"
    },
    {
      "DOI": "10.1016/j.bbamcr.2012.06.012",
      "author": "MB Kannan",
      "doi-asserted-by": "publisher",
      "first-page": "1841",
      "journal-title": "Biochim Biophys Acta",
      "key": "533_CR74",
      "unstructured": "Kannan MB, Solovieva V, Blank V (2012) The small MAF transcription factors MAFF, MAFG and MAFK: Current knowledge and perspectives. Biochim Biophys Acta 1823:1841–1846",
      "volume": "1823",
      "year": "2012"
    },
    {
      "DOI": "10.1128/MCB.15.4.2180",
      "author": "K Kataoka",
      "doi-asserted-by": "publisher",
      "first-page": "2180",
      "journal-title": "Mol Cell Biol",
      "key": "533_CR75",
      "unstructured": "Kataoka K, Igarashi K, Itoh K, Fujiwara KT, Noda M, Yamamoto M et al. (1995) Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. Mol Cell Biol 15:2180–2190",
      "volume": "15",
      "year": "1995"
    },
    {
      "DOI": "10.1093/annonc/mdx286",
      "author": "L Khoja",
      "doi-asserted-by": "publisher",
      "first-page": "2377",
      "journal-title": "Ann Oncol",
      "key": "533_CR76",
      "unstructured": "Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377–2385",
      "volume": "28",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.it.2020.08.010",
      "author": "H-J Kim",
      "doi-asserted-by": "publisher",
      "first-page": "948",
      "journal-title": "Trends Immunol",
      "key": "533_CR77",
      "unstructured": "Kim H-J, Cantor H, Cosmopoulos K (2020) Overcoming immune checkpoint blockade resistance via EZH2 inhibition. Trends Immunol 41:948–963",
      "volume": "41",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.devcel.2006.09.009",
      "author": "WP Kloosterman",
      "doi-asserted-by": "publisher",
      "first-page": "441",
      "journal-title": "Dev Cell",
      "key": "533_CR78",
      "unstructured": "Kloosterman WP, Plasterk RHA (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441–450",
      "volume": "11",
      "year": "2006"
    },
    {
      "DOI": "10.1038/s41598-020-79889-5",
      "author": "S Ko",
      "doi-asserted-by": "publisher",
      "journal-title": "Sci Rep.",
      "key": "533_CR79",
      "unstructured": "Ko S, Choi J, Ahn J (2021) GVES: machine learning model for identification of prognostic genes with a small dataset. Sci Rep. 11:439",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1073/pnas.1802166115",
      "doi-asserted-by": "crossref",
      "key": "533_CR80",
      "unstructured": "Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P et al. (2018) Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1). Proc Natl Acad Sci USA 115:E10119–E10126"
    },
    {
      "DOI": "10.3389/fgene.2020.610798",
      "author": "M Krassowski",
      "doi-asserted-by": "publisher",
      "first-page": "610798",
      "journal-title": "Front Genet",
      "key": "533_CR81",
      "unstructured": "Krassowski M, Das V, Sahu SK, Misra BB (2020) State of the field in multi-omics research: from computational needs to data mining and sharing. Front Genet 11:610798",
      "volume": "11",
      "year": "2020"
    },
    {
      "DOI": "10.1186/1868-7083-5-7",
      "author": "K Kullmann",
      "doi-asserted-by": "publisher",
      "first-page": "7",
      "journal-title": "Clin Epigenet",
      "key": "533_CR82",
      "unstructured": "Kullmann K, Deryal M, Ong MF, Schmidt W, Mahlknecht U (2013) DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population. Clin Epigenet 5:7",
      "volume": "5",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.cell.2018.01.029",
      "author": "SA Lambert",
      "doi-asserted-by": "publisher",
      "first-page": "650",
      "journal-title": "Cell",
      "key": "533_CR83",
      "unstructured": "Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M et al. (2018) The human transcription factors. Cell 172:650–665",
      "volume": "172",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1357-2725(97)00085-X",
      "author": "DS Latchman",
      "doi-asserted-by": "publisher",
      "first-page": "1305",
      "journal-title": "Int J Biochem Cell Biol",
      "key": "533_CR84",
      "unstructured": "Latchman DS (1997) Transcription factors: an overview. Int J Biochem Cell Biol 29:1305–1312",
      "volume": "29",
      "year": "1997"
    },
    {
      "DOI": "10.3389/fgene.2019.00452",
      "author": "M Leclercq",
      "doi-asserted-by": "publisher",
      "first-page": "452",
      "journal-title": "Front Genet",
      "key": "533_CR85",
      "unstructured": "Leclercq M, Vittrant B, Martin-Magniette ML, Scott Boyer MP, Perin O, Bergeron A et al. (2019) Large-scale automatic feature selection for biomarker discovery in high-dimensional OMICs data. Front Genet 10:452",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1146/annurev.genet.34.1.77",
      "author": "TI Lee",
      "doi-asserted-by": "publisher",
      "first-page": "77",
      "journal-title": "Annu Rev Genet",
      "key": "533_CR86",
      "unstructured": "Lee TI, Young RA (2000) Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34:77–137",
      "volume": "34",
      "year": "2000"
    },
    {
      "DOI": "10.1016/j.ebiom.2016.10.028",
      "author": "H Li",
      "doi-asserted-by": "publisher",
      "first-page": "125",
      "journal-title": "EBioMedicine",
      "key": "533_CR87",
      "unstructured": "Li H, Li W, Liu S, Zong S, Wang W, Ren J et al. (2016) DNMT1, DNMT3A and DNMT3B polymorphisms associated with gastric cancer risk: a systematic review and meta-analysis. EBioMedicine 13:125–131",
      "volume": "13",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41388-020-01636-x",
      "author": "X Li",
      "doi-asserted-by": "publisher",
      "first-page": "1836",
      "journal-title": "Oncogene",
      "key": "533_CR88",
      "unstructured": "Li X, Su X, Liu R, Pan Y, Fang J, Cao L et al. (2021) HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene 40:1836–1850",
      "volume": "40",
      "year": "2021"
    },
    {
      "DOI": "10.1007/s002620050324",
      "author": "J Li",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "journal-title": "Cancer Immunol Immunother",
      "key": "533_CR89",
      "unstructured": "Li J, Yang Y, Inoue H, Mori M, Akiyoshi T (1996) The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon γ and interleukin-10. Cancer Immunol Immunother 43:213–219",
      "volume": "43",
      "year": "1996"
    },
    {
      "DOI": "10.3389/fonc.2019.00518",
      "author": "J Li",
      "doi-asserted-by": "publisher",
      "first-page": "518",
      "journal-title": "Front Oncol",
      "key": "533_CR90",
      "unstructured": "Li J, Zhang Z, Chen F, Hu T, Peng W, Gu Q et al. (2019) The diverse oncogenic and tumor suppressor roles of microRNA-105 in cancer. Front Oncol 9:518",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1073/pnas.2014562118",
      "author": "F Li",
      "doi-asserted-by": "publisher",
      "first-page": "e2014562118",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "533_CR91",
      "unstructured": "Li F, Zhao X, Zhang Y, Shao P, Ma X, Paradee WJ et al. (2021) T FH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function. Proc Natl Acad Sci USA 118:e2014562118",
      "volume": "118",
      "year": "2021"
    },
    {
      "DOI": "10.1073/pnas.1804506115",
      "doi-asserted-by": "crossref",
      "key": "533_CR92",
      "unstructured": "Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T et al. (2018) Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Proc Natl Acad Sci USA 115"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-09-4161",
      "author": "R-K Lin",
      "doi-asserted-by": "publisher",
      "first-page": "5807",
      "journal-title": "Cancer Res",
      "key": "533_CR93",
      "unstructured": "Lin R-K, Wu C-Y, Chang J-W, Juan L-J, Hsu H-S, Chen C-Y et al. (2010) Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 70:5807–5817",
      "volume": "70",
      "year": "2010"
    },
    {
      "DOI": "10.1007/s00262-018-2283-0",
      "author": "D Llopiz",
      "doi-asserted-by": "publisher",
      "first-page": "379",
      "journal-title": "Cancer Immunol Immunother",
      "key": "533_CR94",
      "unstructured": "Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J et al. (2019) Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 68:379–393",
      "volume": "68",
      "year": "2019"
    },
    {
      "DOI": "10.3389/fphar.2021.701690",
      "author": "J Ma",
      "doi-asserted-by": "publisher",
      "first-page": "701690",
      "journal-title": "Front Pharm",
      "key": "533_CR95",
      "unstructured": "Ma J, Ge Z (2021) Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front Pharm 12:701690",
      "volume": "12",
      "year": "2021"
    },
    {
      "DOI": "10.1182/blood.V96.12.3847",
      "author": "T Maeda",
      "doi-asserted-by": "publisher",
      "first-page": "3847",
      "journal-title": "Blood",
      "key": "533_CR96",
      "unstructured": "Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847–3856",
      "volume": "96",
      "year": "2000"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-16-0416",
      "author": "M Makvandi",
      "doi-asserted-by": "publisher",
      "first-page": "4516",
      "journal-title": "Cancer Res",
      "key": "533_CR97",
      "unstructured": "Makvandi M, Xu K, Lieberman BP, Anderson R-C, Effron SS, Winters HD et al. (2016) A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res 76:4516–4524",
      "volume": "76",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s00592-019-01402-w",
      "author": "L Marchand",
      "doi-asserted-by": "publisher",
      "first-page": "1239",
      "journal-title": "Acta Diabetol",
      "key": "533_CR98",
      "unstructured": "Marchand L, Disse E, Dalle S, Reffet S, Vouillarmet J, Fabien N et al. (2019) The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors. Acta Diabetol 56:1239–1245",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.1084/jem.20062342",
      "author": "C McCarthy",
      "doi-asserted-by": "publisher",
      "first-page": "1131",
      "journal-title": "J Exp Med",
      "key": "533_CR99",
      "unstructured": "McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA et al. (2007) The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 204:1131–1144",
      "volume": "204",
      "year": "2007"
    },
    {
      "DOI": "10.1038/nrc1779",
      "author": "S Minucci",
      "doi-asserted-by": "publisher",
      "first-page": "38",
      "journal-title": "Nat Rev Cancer",
      "key": "533_CR100",
      "unstructured": "Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51",
      "volume": "6",
      "year": "2006"
    },
    {
      "DOI": "10.1038/25764",
      "author": "CRF Monks",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "journal-title": "Nature",
      "key": "533_CR101",
      "unstructured": "Monks CRF, Freiberg BA, Kupfer H, Sciaky N, Kupfer A (1998) Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82–86",
      "volume": "395",
      "year": "1998"
    },
    {
      "DOI": "10.1101/gad.255182.114",
      "author": "MA Morgan",
      "doi-asserted-by": "publisher",
      "first-page": "238",
      "journal-title": "Genes Dev",
      "key": "533_CR102",
      "unstructured": "Morgan MA, Shilatifard A (2015) Chromatin signatures of cancer. Genes Dev 29:238–249",
      "volume": "29",
      "year": "2015"
    },
    {
      "DOI": "10.1186/s40425-018-0344-8",
      "author": "C Morrison",
      "doi-asserted-by": "publisher",
      "journal-title": "J Immunother Cancer",
      "key": "533_CR103",
      "unstructured": "Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D et al. (2018) Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer 6:32",
      "volume": "6",
      "year": "2018"
    },
    {
      "DOI": "10.3332/ecancer.2019.904",
      "doi-asserted-by": "crossref",
      "key": "533_CR104",
      "unstructured": "Murthy P, Muggia F (2019) Women’s cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. ecancer 13"
    },
    {
      "DOI": "10.1097/CJI.0000000000000385",
      "author": "GS Naik",
      "doi-asserted-by": "publisher",
      "first-page": "307",
      "journal-title": "J Immunother",
      "key": "533_CR105",
      "unstructured": "Naik GS, Buchbinder EI, Cohen JV, Manos MP, Johnson AEW, Bowling P et al. (2021) Long-term overall survival and predictors in Anti–PD-1-naive melanoma patients with brain metastases treated with immune checkpoint inhibitors in the real-world setting: a multicohort study. J Immunother 44:307–318",
      "volume": "44",
      "year": "2021"
    },
    {
      "DOI": "10.1016/S1043-2760(00)00248-4",
      "author": "J Newell-Price",
      "doi-asserted-by": "publisher",
      "first-page": "142",
      "journal-title": "Trends Endocrinol Metab",
      "key": "533_CR106",
      "unstructured": "Newell-Price J, Clark AJL, King P (2000) DNA methylation and silencing of gene expression. Trends Endocrinol Metab 11:142–148",
      "volume": "11",
      "year": "2000"
    },
    {
      "DOI": "10.3390/epigenomes1010003",
      "author": "M Nguyen",
      "doi-asserted-by": "publisher",
      "first-page": "3",
      "journal-title": "Epigenomes",
      "key": "533_CR107",
      "unstructured": "Nguyen M, Dobosz P (2017) New frontiers in melanoma epigenetics—the more we know, the more we don’t know. Epigenomes 1:3",
      "volume": "1",
      "year": "2017"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-12-1972",
      "author": "CJ Nirschl",
      "doi-asserted-by": "publisher",
      "first-page": "4917",
      "journal-title": "Clin Cancer Res",
      "key": "533_CR108",
      "unstructured": "Nirschl CJ, Drake CG (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19:4917–4924",
      "volume": "19",
      "year": "2013"
    },
    {
      "author": "MA Norcross",
      "first-page": "113",
      "journal-title": "Ann Immunol",
      "key": "533_CR109",
      "unstructured": "Norcross MA (1984) A synaptic basis for T-lymphocyte activation. Ann Immunol 135:113–134",
      "volume": "135",
      "year": "1984"
    },
    {
      "DOI": "10.3389/fendo.2018.00402",
      "author": "J O’Brien",
      "doi-asserted-by": "publisher",
      "first-page": "402",
      "journal-title": "Front Endocrinol",
      "key": "533_CR110",
      "unstructured": "O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402",
      "volume": "9",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41591-021-01388-5",
      "author": "M Ogishi",
      "doi-asserted-by": "publisher",
      "first-page": "1646",
      "journal-title": "Nat Med",
      "key": "533_CR111",
      "unstructured": "Ogishi M, Yang R, Aytekin C, Langlais D, Bourgey M, Khan T et al. (2021) Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med 27:1646–1654",
      "volume": "27",
      "year": "2021"
    },
    {
      "DOI": "10.3390/ijms20194781",
      "author": "M Olivier",
      "doi-asserted-by": "publisher",
      "first-page": "4781",
      "journal-title": "IJMS",
      "key": "533_CR112",
      "unstructured": "Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA (2019) The need for multi-omics biomarker signatures in precision medicine. IJMS 20:4781",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1038/nri2381",
      "author": "JS Orange",
      "doi-asserted-by": "publisher",
      "first-page": "713",
      "journal-title": "Nat Rev Immunol",
      "key": "533_CR113",
      "unstructured": "Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8:713–725",
      "volume": "8",
      "year": "2008"
    },
    {
      "DOI": "10.1073/pnas.2120540119",
      "author": "E Oreskovic",
      "doi-asserted-by": "publisher",
      "first-page": "e2120540119",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "533_CR114",
      "unstructured": "Oreskovic E, Wheeler EC, Mengwasser KE, Fujimura E, Martin TD, Tothova Z et al. (2022) Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc Natl Acad Sci USA 119:e2120540119",
      "volume": "119",
      "year": "2022"
    },
    {
      "DOI": "10.1007/s00428-019-02538-4",
      "author": "M Ottaviano",
      "doi-asserted-by": "publisher",
      "first-page": "421",
      "journal-title": "Virchows Arch",
      "key": "533_CR115",
      "unstructured": "Ottaviano M, De Placido S, Ascierto PA (2019) Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Arch 474:421–432",
      "volume": "474",
      "year": "2019"
    },
    {
      "DOI": "10.1073/pnas.1814700116",
      "author": "A Pacis",
      "doi-asserted-by": "publisher",
      "first-page": "6938",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "533_CR116",
      "unstructured": "Pacis A, Mailhot-Léonard F, Tailleux L, Randolph HE, Yotova V, Dumaine A et al. (2019) Gene activation precedes DNA demethylation in response to infection in human dendritic cells. Proc Natl Acad Sci USA 116:6938–6943",
      "volume": "116",
      "year": "2019"
    },
    {
      "DOI": "10.1038/nrc3239",
      "author": "DM Pardoll",
      "doi-asserted-by": "publisher",
      "first-page": "252",
      "journal-title": "Nat Rev Cancer",
      "key": "533_CR117",
      "unstructured": "Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264",
      "volume": "12",
      "year": "2012"
    },
    {
      "DOI": "10.1002/mc.10033",
      "author": "SK Patra",
      "doi-asserted-by": "publisher",
      "first-page": "163",
      "journal-title": "Mol Carcinog",
      "key": "533_CR118",
      "unstructured": "Patra SK, Patra A, Zhao H, Dahiya R (2002) DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 33:163–171",
      "volume": "33",
      "year": "2002"
    },
    {
      "DOI": "10.1126/sciadv.abd2712",
      "author": "N Patsoukis",
      "doi-asserted-by": "publisher",
      "first-page": "eabd2712",
      "journal-title": "Sci Adv",
      "key": "533_CR119",
      "unstructured": "Patsoukis N, Wang Q, Strauss L, Boussiotis VA (2020) Revisiting the PD-1 pathway. Sci Adv 6:eabd2712",
      "volume": "6",
      "year": "2020"
    },
    {
      "DOI": "10.1021/acs.jproteome.0c00641",
      "author": "A Petrera",
      "doi-asserted-by": "publisher",
      "first-page": "751",
      "journal-title": "J Proteome Res",
      "key": "533_CR120",
      "unstructured": "Petrera A, von Toerne C, Behler J, Huth C, Thorand B, Hilgendorff A et al. (2021) Multiplatform approach for plasma proteomics: complementarity of olink proximity extension assay technology to mass spectrometry-based protein profiling. J Proteome Res 20:751–762",
      "volume": "20",
      "year": "2021"
    },
    {
      "DOI": "10.1214/17-BA1082",
      "doi-asserted-by": "crossref",
      "key": "533_CR121",
      "unstructured": "Polson NG, Sokolov V (2017) Deep learning: a Bayesian perspective. Bayesian Anal 12"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-16-3556",
      "author": "A Prat",
      "doi-asserted-by": "publisher",
      "first-page": "3540",
      "journal-title": "Cancer Res",
      "key": "533_CR122",
      "unstructured": "Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T et al. (2017) Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res 77:3540–3550",
      "volume": "77",
      "year": "2017"
    },
    {
      "DOI": "10.1158/2159-8290.CD-16-1022",
      "author": "A Qamra",
      "doi-asserted-by": "publisher",
      "first-page": "630",
      "journal-title": "Cancer Disco",
      "key": "533_CR123",
      "unstructured": "Qamra A, Xing M, Padmanabhan N, Kwok JJT, Zhang S, Xu C et al. (2017) Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma. Cancer Disco 7:630–651",
      "volume": "7",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s13075-021-02664-y",
      "author": "Y Qi",
      "doi-asserted-by": "publisher",
      "first-page": "279",
      "journal-title": "Arthritis Res Ther",
      "key": "533_CR124",
      "unstructured": "Qi Y, Zhao X, Liu X, Wang Y, Zhai Y, Zhang X et al. (2021) Lupus susceptibility region containing CTLA4 rs17268364 functionally reduces CTLA4 expression by binding EWSR1 and correlates IFN-α signature. Arthritis Res Ther 23:279",
      "volume": "23",
      "year": "2021"
    },
    {
      "DOI": "10.3389/fgene.2019.00110",
      "author": "H Qin",
      "doi-asserted-by": "publisher",
      "first-page": "110",
      "journal-title": "Front Genet",
      "key": "533_CR125",
      "unstructured": "Qin H, Niu T, Zhao J (2019) Identifying multi-omics causers and causal pathways for complex traits. Front Genet 10:110",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s12943-019-1091-2",
      "author": "S Qin",
      "doi-asserted-by": "publisher",
      "journal-title": "Mol Cancer",
      "key": "533_CR126",
      "unstructured": "Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18:155",
      "volume": "18",
      "year": "2019"
    },
    {
      "DOI": "10.1101/gad.276568.115",
      "author": "KD Rasmussen",
      "doi-asserted-by": "publisher",
      "first-page": "733",
      "journal-title": "Genes Dev",
      "key": "533_CR127",
      "unstructured": "Rasmussen KD, Helin K (2016) Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 30:733–750",
      "volume": "30",
      "year": "2016"
    },
    {
      "DOI": "10.1056/NEJMoa1606774",
      "author": "M Reck",
      "doi-asserted-by": "publisher",
      "first-page": "1823",
      "journal-title": "N Engl J Med",
      "key": "533_CR128",
      "unstructured": "Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833",
      "volume": "375",
      "year": "2016"
    },
    {
      "DOI": "10.1200/JCO.2016.66.4482",
      "author": "MGM Roemer",
      "doi-asserted-by": "publisher",
      "first-page": "2690",
      "journal-title": "JCO",
      "key": "533_CR129",
      "unstructured": "Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H et al. (2016) PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. JCO 34:2690–2697",
      "volume": "34",
      "year": "2016"
    },
    {
      "DOI": "10.1146/annurev.biochem.70.1.81",
      "author": "SY Roth",
      "doi-asserted-by": "publisher",
      "first-page": "81",
      "journal-title": "Annu Rev Biochem",
      "key": "533_CR130",
      "unstructured": "Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81–120",
      "volume": "70",
      "year": "2001"
    },
    {
      "DOI": "10.1186/s13046-019-1259-z",
      "author": "A Rotte",
      "doi-asserted-by": "publisher",
      "first-page": "255",
      "journal-title": "J Exp Clin Cancer Res",
      "key": "533_CR131",
      "unstructured": "Rotte A (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38:255",
      "volume": "38",
      "year": "2019"
    },
    {
      "DOI": "10.1038/ni.3441",
      "author": "R Roychoudhuri",
      "doi-asserted-by": "publisher",
      "first-page": "851",
      "journal-title": "Nat Immunol",
      "key": "533_CR132",
      "unstructured": "Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA et al. (2016) BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol 17:851–860",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nature12199",
      "author": "R Roychoudhuri",
      "doi-asserted-by": "publisher",
      "first-page": "506",
      "journal-title": "Nature",
      "key": "533_CR133",
      "unstructured": "Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M et al. (2013) BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature 498:506–510",
      "volume": "498",
      "year": "2013"
    },
    {
      "DOI": "10.3332/ecancer.2020.1150",
      "doi-asserted-by": "crossref",
      "key": "533_CR134",
      "unstructured": "Sajjadi E, Venetis K, Scatena C, Fusco N (2020) Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? ecancer 14"
    },
    {
      "DOI": "10.1186/1756-8935-8-3",
      "author": "N Saksouk",
      "doi-asserted-by": "publisher",
      "first-page": "3",
      "journal-title": "Epigenetics Chromatin",
      "key": "533_CR135",
      "unstructured": "Saksouk N, Simboeck E, Déjardin J (2015) Constitutive heterochromatin formation and transcription in mammals. Epigenetics Chromatin 8:3",
      "volume": "8",
      "year": "2015"
    },
    {
      "DOI": "10.1038/sj.onc.1203716",
      "author": "S Sasaki",
      "doi-asserted-by": "publisher",
      "first-page": "3739",
      "journal-title": "Oncogene",
      "key": "533_CR136",
      "unstructured": "Sasaki S, Ito E, Toki T, Maekawa T, Kanezaki R, Umenai T et al. (2000) Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15. Oncogene 19:3739–3749",
      "volume": "19",
      "year": "2000"
    },
    {
      "DOI": "10.1016/S0140-6736(17)31601-X",
      "author": "J Schachter",
      "doi-asserted-by": "publisher",
      "first-page": "1853",
      "journal-title": "Lancet",
      "key": "533_CR137",
      "unstructured": "Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L et al. (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862",
      "volume": "390",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41422-020-0277-x",
      "author": "A Schnell",
      "doi-asserted-by": "publisher",
      "first-page": "285",
      "journal-title": "Cell Res",
      "key": "533_CR138",
      "unstructured": "Schnell A, Bod L, Madi A, Kuchroo VK (2020) The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res 30:285–299",
      "volume": "30",
      "year": "2020"
    },
    {
      "DOI": "10.1371/journal.pone.0179726",
      "author": "NO Siemers",
      "doi-asserted-by": "publisher",
      "first-page": "e0179726",
      "journal-title": "PLoS ONE",
      "key": "533_CR139",
      "unstructured": "Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF et al. (2017) Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors (R Chammas, Ed.). PLoS ONE 12:e0179726",
      "volume": "12",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.gene.2020.144888",
      "author": "N Skafi",
      "doi-asserted-by": "publisher",
      "first-page": "144888",
      "journal-title": "Gene",
      "key": "533_CR140",
      "unstructured": "Skafi N, Fayyad-Kazan M, Badran B (2020) Immunomodulatory role for MicroRNAs: regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression. Gene 754:144888",
      "volume": "754",
      "year": "2020"
    },
    {
      "DOI": "10.1038/bjc.1948.24",
      "author": "DW Smithers",
      "doi-asserted-by": "publisher",
      "first-page": "163",
      "journal-title": "Br J Cancer",
      "key": "533_CR141",
      "unstructured": "Smithers DW (1948) Family histories of 459 patients with cancer of the breast. Br J Cancer 2:163–167",
      "volume": "2",
      "year": "1948"
    },
    {
      "DOI": "10.1093/wentk/9780190234775.001.0001",
      "doi-asserted-by": "publisher",
      "key": "533_CR142",
      "unstructured": "Snyder M (2016) Genomics and personalized medicine: what everyone needs to know®, 1st edn. Oxford University Press. https://doi.org/10.1093/wentk/9780190234775.001.0001"
    },
    {
      "DOI": "10.1200/EDBK_160766",
      "doi-asserted-by": "crossref",
      "key": "533_CR143",
      "unstructured": "Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM (2016) Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book 35:e493–503"
    },
    {
      "DOI": "10.1093/rheumatology/kez418",
      "author": "L Spiers",
      "doi-asserted-by": "publisher",
      "first-page": "vii7",
      "journal-title": "Rheumatology",
      "key": "533_CR144",
      "unstructured": "Spiers L, Coupe N, Payne M (2019) Toxicities associated with checkpoint inhibitors—an overview. Rheumatology 58:vii7–vii16",
      "volume": "58",
      "year": "2019"
    },
    {
      "DOI": "10.1093/intimm/dxw014",
      "author": "S Spranger",
      "doi-asserted-by": "publisher",
      "first-page": "383",
      "journal-title": "INTIMM",
      "key": "533_CR145",
      "unstructured": "Spranger S (2016) Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. INTIMM 28:383–391",
      "volume": "28",
      "year": "2016"
    },
    {
      "DOI": "10.3390/ijms22052553",
      "author": "PA Stempor",
      "doi-asserted-by": "publisher",
      "first-page": "2553",
      "journal-title": "IJMS",
      "key": "533_CR146",
      "unstructured": "Stempor PA, Avni D, Leibowitz R, Sidi Y, Stępień M, Dzieciątkowski T et al. (2021) Comprehensive analysis of correlations in the expression of miRNA genes and immune checkpoint genes in bladder cancer cells. IJMS 22:2553",
      "volume": "22",
      "year": "2021"
    },
    {
      "DOI": "10.18632/oncotarget.7593",
      "author": "M Straub",
      "doi-asserted-by": "publisher",
      "first-page": "12024",
      "journal-title": "Oncotarget",
      "key": "533_CR147",
      "unstructured": "Straub M, Drecoll E, Pfarr N, Weichert W, Langer R, Hapfelmeier A et al. (2016) CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 7:12024–12034",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.3389/fonc.2014.00080",
      "doi-asserted-by": "crossref",
      "key": "533_CR148",
      "unstructured": "Subramaniam D, Thombre R, Dhar A, Anant S (2014) DNA Methyltransferases: a novel target for prevention and therapy. Front Oncol 4"
    },
    {
      "DOI": "10.1177/1177932219899051",
      "author": "I Subramanian",
      "doi-asserted-by": "publisher",
      "first-page": "117793221989905",
      "journal-title": "Bioinform Biol Insights",
      "key": "533_CR149",
      "unstructured": "Subramanian I, Verma S, Kumar S, Jere A, Anamika K (2020) Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights 14:117793221989905",
      "volume": "14",
      "year": "2020"
    },
    {
      "DOI": "10.3322/caac.21660",
      "author": "H Sung",
      "doi-asserted-by": "publisher",
      "first-page": "209",
      "journal-title": "CA A Cancer J Clin",
      "key": "533_CR150",
      "unstructured": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249",
      "volume": "71",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.nbd.2020.105060",
      "author": "RK Suter",
      "doi-asserted-by": "publisher",
      "first-page": "105060",
      "journal-title": "Neurobiol Dis",
      "key": "533_CR151",
      "unstructured": "Suter RK, Rodriguez-Blanco J, Ayad NG (2020) Epigenetic pathways and plasticity in brain tumors. Neurobiol Dis 145:105060",
      "volume": "145",
      "year": "2020"
    },
    {
      "DOI": "10.1186/1471-2164-16-S1-S2",
      "author": "AL Swan",
      "doi-asserted-by": "publisher",
      "journal-title": "BMC Genomics",
      "key": "533_CR152",
      "unstructured": "Swan AL, Stekel DJ, Hodgman C, Allaway D, Alqahtani MH, Mobasheri A et al. (2015) A machine learning heuristic to identify biologically relevant and minimal biomarker panels from omics data. BMC Genomics 16:S2",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1002/cac2.12023",
      "author": "WCC Tan",
      "doi-asserted-by": "publisher",
      "first-page": "135",
      "journal-title": "Cancer Commun",
      "key": "533_CR153",
      "unstructured": "Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF et al. (2020) Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun 40:135–153",
      "volume": "40",
      "year": "2020"
    },
    {
      "DOI": "10.1074/jbc.M305076200",
      "author": "T Tanioka",
      "doi-asserted-by": "publisher",
      "first-page": "32275",
      "journal-title": "J Biol Chem",
      "key": "533_CR154",
      "unstructured": "Tanioka T, Hattori A, Masuda S, Nomura Y, Nakayama H, Mizutani S et al. (2003) Human leukocyte-derived arginine aminopeptidase. J Biol Chem 278:32275–32283",
      "volume": "278",
      "year": "2003"
    },
    {
      "DOI": "10.1038/nature13480",
      "author": "The Cancer Genome Atlas Research Network",
      "doi-asserted-by": "publisher",
      "first-page": "202",
      "journal-title": "Nature",
      "key": "533_CR155",
      "unstructured": "The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209",
      "volume": "513",
      "year": "2014"
    },
    {
      "DOI": "10.1038/ni.3731",
      "author": "AN Theofilopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "716",
      "journal-title": "Nat Immunol",
      "key": "533_CR156",
      "unstructured": "Theofilopoulos AN, Kono DH, Baccala R (2017) The multiple pathways to autoimmunity. Nat Immunol 18:716–724",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.immuni.2018.03.023",
      "author": "V Thorsson",
      "doi-asserted-by": "publisher",
      "first-page": "812",
      "journal-title": "Immunity",
      "key": "533_CR157",
      "unstructured": "Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H et al. (2018) The immune landscape of cancer. Immunity 48:812–830.e14",
      "volume": "48",
      "year": "2018"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-05-1681",
      "author": "I Tirapu",
      "doi-asserted-by": "publisher",
      "first-page": "2442",
      "journal-title": "Cancer Res",
      "key": "533_CR158",
      "unstructured": "Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O et al. (2006) Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 66:2442–2450",
      "volume": "66",
      "year": "2006"
    },
    {
      "DOI": "10.1038/sj.onc.1201024",
      "author": "T Toki",
      "doi-asserted-by": "publisher",
      "first-page": "1901",
      "journal-title": "Oncogene",
      "key": "533_CR159",
      "unstructured": "Toki T, Itoh J, Kitazawa J, Arai K, Hatakeyama K, Akasaka J et al. (1997) Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif. Oncogene 14:1901–1910",
      "volume": "14",
      "year": "1997"
    },
    {
      "DOI": "10.3390/cancers12040935",
      "doi-asserted-by": "crossref",
      "key": "533_CR177",
      "unstructured": "van Elsas MJ, van Hall T, van der Burg SH (2020) Future challenges in cancer resistance to immunotherapy. Cancers 12:935"
    },
    {
      "DOI": "10.1016/j.it.2020.06.002",
      "author": "L Villanueva",
      "doi-asserted-by": "publisher",
      "first-page": "676",
      "journal-title": "Trends Immunol",
      "key": "533_CR160",
      "unstructured": "Villanueva L, Álvarez-Errico D, Esteller M (2020) The contribution of epigenetics to cancer immunotherapy. Trends Immunol 41:676–691",
      "volume": "41",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41577-020-0306-5",
      "author": "AD Waldman",
      "doi-asserted-by": "publisher",
      "first-page": "651",
      "journal-title": "Nat Rev Immunol",
      "key": "533_CR162",
      "unstructured": "Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651–668",
      "volume": "20",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.cellsig.2014.12.003",
      "author": "X Wang",
      "doi-asserted-by": "publisher",
      "first-page": "443",
      "journal-title": "Cell Signal",
      "key": "533_CR163",
      "unstructured": "Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y et al. (2015) Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 27:443–452",
      "volume": "27",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s10529-017-2397-z",
      "author": "Y Wang",
      "doi-asserted-by": "publisher",
      "first-page": "1485",
      "journal-title": "Biotechnol Lett",
      "key": "533_CR164",
      "unstructured": "Wang Y, Wang L (2017) miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechnol Lett 39:1485–1492",
      "volume": "39",
      "year": "2017"
    },
    {
      "DOI": "10.1182/bloodadvances.2019001012",
      "author": "K Wienand",
      "doi-asserted-by": "publisher",
      "first-page": "4065",
      "journal-title": "Blood Adv",
      "key": "533_CR165",
      "unstructured": "Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J et al. (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3:4065–4080",
      "volume": "3",
      "year": "2019"
    },
    {
      "DOI": "10.1158/2326-6066.CIR-15-0077-T",
      "author": "DM Woods",
      "doi-asserted-by": "publisher",
      "first-page": "1375",
      "journal-title": "Cancer Immunol Res",
      "key": "533_CR166",
      "unstructured": "Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J (2015) HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res 3:1375–1385",
      "volume": "3",
      "year": "2015"
    },
    {
      "DOI": "10.1007/978-3-642-03858-7_5",
      "doi-asserted-by": "crossref",
      "key": "533_CR167",
      "unstructured": "Yokosuka T, Saito T (2010) The immunological synapse, TCR microclusters, and T cell activation. In: Saito T, Batista FD (eds) Immunological synapse, current topics in microbiology and immunology, vol 340. Springer Berlin Heidelberg, Berlin, Heidelberg, p 81–107"
    },
    {
      "DOI": "10.1038/s41388-018-0303-3",
      "author": "I Zerdes",
      "doi-asserted-by": "publisher",
      "first-page": "4639",
      "journal-title": "Oncogene",
      "key": "533_CR168",
      "unstructured": "Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37:4639–4661",
      "volume": "37",
      "year": "2018"
    },
    {
      "DOI": "10.1186/s13046-021-01987-7",
      "author": "H Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "184",
      "journal-title": "J Exp Clin Cancer Res",
      "key": "533_CR169",
      "unstructured": "Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L et al. (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 40:184",
      "volume": "40",
      "year": "2021"
    },
    {
      "DOI": "10.3389/fonc.2021.582664",
      "author": "W Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "582664",
      "journal-title": "Front Oncol",
      "key": "533_CR170",
      "unstructured": "Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N et al. (2021) Research progresses in immunological checkpoint inhibitors for breast cancer immunotherapy. Front Oncol 11:582664",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41524-018-0081-z",
      "author": "Y Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "25",
      "journal-title": "npj Comput Mater",
      "key": "533_CR171",
      "unstructured": "Zhang Y, Ling C (2018) A strategy to apply machine learning to small datasets in materials science. npj Comput Mater 4:25",
      "volume": "4",
      "year": "2018"
    },
    {
      "DOI": "10.3390/cancers12082123",
      "author": "J Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "2123",
      "journal-title": "Cancers",
      "key": "533_CR172",
      "unstructured": "Zhang J, Yang C, Wu C, Cui W, Wang L (2020) DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy. Cancers 12:2123",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41423-020-0488-6",
      "author": "Y Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "807",
      "journal-title": "Cell Mol Immunol",
      "key": "533_CR173",
      "unstructured": "Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821",
      "volume": "17",
      "year": "2020"
    },
    {
      "DOI": "10.3892/or.2017.5992",
      "author": "X Zhao",
      "doi-asserted-by": "publisher",
      "first-page": "2727",
      "journal-title": "Oncol Rep",
      "key": "533_CR174",
      "unstructured": "Zhao X, Ji Z, Xie Y, Liu G, Li H (2017) MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2. Oncol Rep 38:2727–2734",
      "volume": "38",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.celrep.2017.07.007",
      "author": "D Zingg",
      "doi-asserted-by": "publisher",
      "first-page": "854",
      "journal-title": "Cell Rep",
      "key": "533_CR175",
      "unstructured": "Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J et al. (2017) The Histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep 20:854–867",
      "volume": "20",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.diabres.2018.05.044",
      "author": "M Zurawek",
      "doi-asserted-by": "publisher",
      "first-page": "146",
      "journal-title": "Diabetes Res Clin Pract",
      "key": "533_CR176",
      "unstructured": "Zurawek M, Dzikiewicz-Krawczyk A, Izykowska K, Ziolkowska-Suchanek I, Skowronska B, Czainska M et al. (2018) miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract 142:146–153",
      "volume": "142",
      "year": "2018"
    }
  ],
  "reference-count": 175,
  "references-count": 175,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41437-022-00533-1"
    }
  },
  "score": 0,
  "short-container-title": [
    "Heredity"
  ],
  "source": "Crossref",
  "title": [
    "Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "129"
}